Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s
Donanemab Has Dosing, Cost Advantages Over Eisai/Biogen Drug
The US FDA approved Lilly’s Kisunla (donanemab) for early Alzheimer’s disease and the anti-amyloid antibody will launch into a challenging market primed by Eisai/Biogen’s Leqembi.
